Literature DB >> 30511500

Bayesian model of disease progression in GNE myopathy.

M Quintana1, J Shrader2, C Slota3,4, G Joe2, J C McKew3, M Fitzgerald1, W A Gahl5, S Berry1,6, N Carrillo3,5.   

Abstract

One Sentence Summary: A Bayesian repeated measures model based on quantitative muscle strength data from a prospective Natural History Study was developed to determine disease progression and design clinical trials for GNE myopathy, a rare and slowly progressive muscle disease. GNE myopathy is a rare muscle disease characterized by slowly progressive weakness and atrophy of skeletal muscles. To address the significant challenges of defining the natural history and designing clinical trials for GNE myopathy, we developed a Bayesian latent variable repeated measures model to determine disease progression. The model is based on longitudinal quantitative muscle strength data collected as part of a prospective Natural History Study. The GNE Myopathy Progression Model provides an understanding of disease progression that would have otherwise required a natural history of unfeasible duration. "Disease age," the model-generated measure of disease progression, highly correlates with a variety of clinical, functional and patient-reported outcomes. With the incorporation of a treatment effect parameter to the GNE Disease Progression Model, we describe a novel GNE Myopathy Disease Modification Analysis that significantly increases power and reduces the number of subjects required to test the effectiveness of novel therapies when compared to more traditional analysis methods. The GNE Myopathy Disease Progression Model and Disease Modification Analysis can be applied to muscle diseases with prospectively collected muscle strength data, and a variety of rare and slowly progressive diseases. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Bayesian; GNE myopathy; clinical trial; disease progression model; muscle disease

Mesh:

Year:  2018        PMID: 30511500     DOI: 10.1002/sim.8050

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Temporal order of clinical and biomarker changes in familial frontotemporal dementia.

Authors:  Adam M Staffaroni; Melanie Quintana; Barbara Wendelberger; Hilary W Heuer; Lucy L Russell; Yann Cobigo; Amy Wolf; Sheng-Yang Matt Goh; Leonard Petrucelli; Tania F Gendron; Carolin Heller; Annie L Clark; Jack Carson Taylor; Amy Wise; Elise Ong; Leah Forsberg; Danielle Brushaber; Julio C Rojas; Lawren VandeVrede; Peter Ljubenkov; Joel Kramer; Kaitlin B Casaletto; Brian Appleby; Yvette Bordelon; Hugo Botha; Bradford C Dickerson; Kimiko Domoto-Reilly; Julie A Fields; Tatiana Foroud; Ralitza Gavrilova; Daniel Geschwind; Nupur Ghoshal; Jill Goldman; Jonathon Graff-Radford; Neill Graff-Radford; Murray Grossman; Matthew G H Hall; Ging-Yuek Hsiung; Edward D Huey; David Irwin; David T Jones; Kejal Kantarci; Daniel Kaufer; David Knopman; Walter Kremers; Argentina Lario Lago; Maria I Lapid; Irene Litvan; Diane Lucente; Ian R Mackenzie; Mario F Mendez; Carly Mester; Bruce L Miller; Chiadi U Onyike; Rosa Rademakers; Vijay K Ramanan; Eliana Marisa Ramos; Meghana Rao; Katya Rascovsky; Katherine P Rankin; Erik D Roberson; Rodolfo Savica; M Carmela Tartaglia; Sandra Weintraub; Bonnie Wong; David M Cash; Arabella Bouzigues; Imogen J Swift; Georgia Peakman; Martina Bocchetta; Emily G Todd; Rhian S Convery; James B Rowe; Barbara Borroni; Daniela Galimberti; Pietro Tiraboschi; Mario Masellis; Elizabeth Finger; John C van Swieten; Harro Seelaar; Lize C Jiskoot; Sandro Sorbi; Chris R Butler; Caroline Graff; Alexander Gerhard; Tobias Langheinrich; Robert Laforce; Raquel Sanchez-Valle; Alexandre de Mendonça; Fermin Moreno; Matthis Synofzik; Rik Vandenberghe; Simon Ducharme; Isabelle Le Ber; Johannes Levin; Adrian Danek; Markus Otto; Florence Pasquier; Isabel Santana; John Kornak; Bradley F Boeve; Howard J Rosen; Jonathan D Rohrer; Adam L Boxer
Journal:  Nat Med       Date:  2022-09-22       Impact factor: 87.241

2.  Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.

Authors:  Janelle L Lennie; John T Mondick; Marc R Gastonguay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-01-20       Impact factor: 2.745

3.  Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy.

Authors:  Eve Fouarge; Arnaud Monseur; Bruno Boulanger; Mélanie Annoussamy; Andreea M Seferian; Silvana De Lucia; Charlotte Lilien; Leen Thielemans; Khazal Paradis; Belinda S Cowling; Chris Freitag; Bradley P Carlin; Laurent Servais
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

4.  Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE Myopathy.

Authors:  Hanns Lochmüller; Anthony Behin; Ivailo Tournev; Mark Tarnopolsky; Rita Horváth; Oksana Pogoryelova; Jinay Shah; Tony Koutsoukos; Alison Skrinar; Emil Kakkis; Camille L Bedrosian; Tahseen Mozaffar
Journal:  J Neuromuscul Dis       Date:  2021

Review 5.  Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.

Authors:  Kelley M Kidwell; Satrajit Roychoudhury; Barbara Wendelberger; John Scott; Tara Moroz; Shaoming Yin; Madhurima Majumder; John Zhong; Raymond A Huml; Veronica Miller
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303

6.  Skeletal Muscle Magnetic Resonance Biomarkers in GNE Myopathy.

Authors:  Chia-Ying Liu; Jianhua Yao; William C Kovacs; Joseph A Shrader; Galen Joe; Ronald Ouwerkerk; Ami K Mankodi; William A Gahl; Ronald M Summers; Nuria Carrillo
Journal:  Neurology       Date:  2020-11-20       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.